

Special Issue

Current and Future Bladder Cancer Landscape

Message from the Guest Editor

Urothelial carcinoma of the bladder is one of the most prevalent cancers worldwide, diagnosed as non-muscle invasive (NMIBC) in 75% of cases, in which cystoscopy, transurethral resection, and intravesical bacillus Calmette–Guérin (BCG) have withstood the test of time, remaining the gold standards, as well as neo-adjuvant cisplatin-based chemotherapy and cystectomy in the muscle-invasive context. Since 2016, the bladder cancer treatment scenario has evolved with the introduction of monoclonal antibodies developed to specifically target immune checkpoint molecules, opening new diagnostic, prognostic, therapeutic, and epidemiological paradigms. This Special Issue will cover the present and future of this evolving landscape.

Guest Editor

Prof. Dr. Leonardo O. Reis

1. Faculty of Medical Sciences, State University of Campinas–UNICAMP, Campinas, São Paulo, Brazil
2. Urologic Oncology Department, PUC-Campinas, School of Life Sciences, Pontifical Catholic University of Campinas, Campinas, São Paulo, Brazil

Deadline for manuscript submissions

closed (31 August 2023)



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 3.3
Indexed in PubMed



mdpi.com/si/139682

Current Oncology
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 3.3
Indexed in PubMed



[mdpi.com/journal/
curroncology](https://mdpi.com/journal/curroncology)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
 2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada
-

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility

: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)